Literature DB >> 24901155

Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue.

Kunitoshi Sakurai, Tetsuro Sohda, Syu-Ichi Ueda, Takashi Tanaka, Genryu Hirano, Keiji Yokoyama, Daisuke Morihara, Akira Aanan, Yasuyuki Takeyama, Makoto Irie, Kaoru Iwata, Satoshi Syakado, Tomoaki Noritomiz, Yuichi Yamashita, Shotaro Sakisaka.   

Abstract

BACKGROUND/AIMS: Recent studies have confirmed that iron overload is involved not only in liver carcinogenesis, but in its progression. Results in studies using liver cancer cell lines have suggested a relationship between transferrin receptor (TfR) expression and liver carcinogenesis, but TfR expression has not yet been analyzed in human hepatocellular carcinoma (HCC) tissues.
METHODOLOGY: We immunohistochemically assessed the expression of TfR1 and TfR2 in tumor tissues and adjacent non-tumorous liver tissues from 41 HCC patients who underwent partial hepatectomy. We evaluated uptake of iron in hepatocytes and HCC cells using iron staining.
RESULTS: The expression TfR was significantly higher in HCC samples than in adjacent non-tumor tissue (p < 0.001). TfR expression was significantly related to serum alpha-fetoprotein (p < 0.05) and des-gamma carboxy prothrombin (p < 0.05) concentrations. We also found iron deposition in non-tumor tissue from 25 patients, but in only two HCC samples, consistent with findings that hepatocellular iron uptake decreases with liver carcinogenesis.
CONCLUSIONS: We investigated the expression of TfR1 and TfR2 in human HCC tissues by immunohistochemistry, the first report demonstrating TfR2 expression immunohistochemically in human HCC. These results suggest that TfR is expressed in response to iron deficiency during liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24901155

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  18 in total

Review 1.  Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies?

Authors:  Christine Pocha; Chencheng Xie
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-09

Review 2.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 3.  Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.

Authors:  Caiguo Zhang; Fan Zhang
Journal:  Protein Cell       Date:  2014-12-06       Impact factor: 14.870

4.  Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase.

Authors:  Jason M Shapiro; Waihong Chung; Kosuke Ogawa; Luke Barker; Rolf Carlson; Jack R Wands; Jisu Li
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

5.  Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas.

Authors:  Cody Weston; Joe Klobusicky; Jennifer Weston; James Connor; Steven A Toms; Nicholas F Marko
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

6.  Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients.

Authors:  Christopher J Greene; Kristopher Attwood; Nitika J Sharma; Kenneth W Gross; Gary J Smith; Bo Xu; Eric C Kauffman
Journal:  Oncotarget       Date:  2017-11-06

7.  Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.

Authors:  Artavazd Arumov; Piumi Y Liyanage; Roger M Leblanc; Jonathan H Schatz; Asaad Trabolsi; Evan R Roberts; Lingxiao Li; Braulio C L B Ferreira; Zhen Gao; Yuguang Ban; Austin D Newsam; Melissa W Taggart; Francisco Vega; Daniel Bilbao
Journal:  Cancer Res       Date:  2020-11-11       Impact factor: 13.312

8.  Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.

Authors:  Wendian Zhang; Fangqi Peng; Taotao Zhou; Yifei Huang; Li Zhang; Peng Ye; Miao Lu; Guang Yang; Yongkang Gai; Tan Yang; Xiang Ma; Guangya Xiang
Journal:  Int J Nanomedicine       Date:  2015-07-29

9.  Mechanisms of Dihydroartemisinin and Dihydroartemisinin/Holotransferrin Cytotoxicity in T-Cell Lymphoma Cells.

Authors:  Qiuyan Wang; Shaoling Wu; Xindong Zhao; Chunting Zhao; Hongguo Zhao; Lanfen Huo
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

10.  MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis.

Authors:  Iryna Kindrat; Volodymyr Tryndyak; Aline de Conti; Svitlana Shpyleva; Thilak K Mudalige; Tetyana Kobets; Anna M Erstenyuk; Frederick A Beland; Igor P Pogribny
Journal:  Oncotarget       Date:  2016-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.